

UNCLASSIFIED

AD NUMBER
ADB258952
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 99. Other requests shall be referred to US Army Medical Research and Materiel Command, Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 26 Aug 2002

THIS PAGE IS UNCLASSIFIED

AD _____

GRANT NUMBER DAMD17-98-1-8228

TITLE: Analysis of Ligand Binding ErbB Receptor Tyrosine Kinases

PRINCIPAL INVESTIGATOR: Kathryn M. Ferguson, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: July 1999

TYPE OF REPORT: Annual *Summary*

PREPARED FOR: Commanding General
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20001019 066

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.


LIMITED RIGHTS LEGEND


Award Number: DAMD17-98-1-8228

Organization: University of Pennsylvania

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.





REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 1999	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 98 - 30 Jun 99)		
4. TITLE AND SUBTITLE Analysis of Ligand Binding ErbB Receptor Tyrosine Kinases		5. FUNDING NUMBERS DAMD17-98-1-8228		Summary
6. AUTHOR(S) Kathryn M. Ferguson, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-3246		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words) Growth factor-receptor tyrosine kinases (RTK's) play a central role in the coordination of cell growth, differentiation and other activities in multicellular organism. Molecular lesions in and/or aberrant expression of RTK's can lead to cancer. There is a particularly strong correlation between the erbB2 (neu/HER-2) receptor and breast cancer. The cell-surface location of the erbB2 receptor makes it an obvious target for novel therapies. The purpose of this research is to gain insight into the structure of the extracellular domain of this receptor and its mode of activation in order to aid in the development of new antagonists. ErbB2 is one of a family of 4 RTK's which also includes the epidermal growth factor receptor (EGFR). The first step in the stimulation of a response by a growth factor is dimerization of the receptor upon binding of the cognate ligand. We have crystals of the EGF induced homodimer of the soluble extracellular domain of EGFR that diffract to better than 2.8 Å. Determination of this structure is in progress. This structure will provide insight into the specific molecular events that drive erbB receptor dimerization. A key question is whether the dimerization is mediated only by receptor-receptor contacts, or whether the ligand is bivalent in nature, simultaneously contacting both receptor molecules in the dimer.				
14. SUBJECT TERMS Breast Cancer erbB receptor: X-ray crystallography: growth factor: protein structure: ligand binding		15. NUMBER OF PAGES 14		
		16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

MMJ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

NA In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

WA For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

WA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

W.M. Loggion 7/30/99
PI - Signature Date

Table of Contents

1.	Front Cover	page 1
2.	Standard Form 298	page 2
3.	Foreword	page 3
4.	Table of Contents	page 4
5.	Introduction	pages 5
6.	Body of Report	page 6-10
7.	Key Research Accomplishments	page 11
8.	Reportable Outcomes	page 11
9.	Conclusions	pages 11
10.	References	page 12

Introduction

Many intracellular communication signals are mediated by hormones and growth factors that bind to specific receptors on the cell surface. These receptors are responsible for transmitting the signal to the inside of the cell where a cascade of events is triggered leading to a cellular response. Many growth factor receptors share a broadly similar architecture; a large extracellular ligand binding domain, a single membrane-spanning domain, and a cytoplasmic domain consisting of a tyrosine kinase domain plus regulatory sequences¹. Receptors of this type, of which there are more than 50, are termed receptor tyrosine kinases (RTK's). Signal transduction through RTK's involves dimerization upon binding of the cognate growth factor resulting in stimulation of the intracellular tyrosine kinase domain of the receptor^{2,3}. Autophosphorylation on specific tyrosines in the RTK leads to the recruitment of downstream signaling molecules through the interaction with their Src homology 2 (SH2) domains⁴. A great deal is known about the protein-protein interactions involved in these downstream events. There have been numerous structures of SH2 domains interacting with phosphopeptides⁵, and the X-ray crystal structures of the tyrosine kinase domains from two receptors have been determined^{6,7}. In contrast there is relatively little structural information about the extracellular domains of RTK's. The molecular interactions that mediate the dimerization event are not understood. Much more is known about the mechanism of receptor dimerization of the cytokine receptor family⁸, which have yielded more readily to biophysical studies⁹⁻¹². The striking picture from the X-ray crystal structure of a single human growth hormone (hGH) molecule simultaneously interacting with two receptor molecules¹⁰ has strongly influenced the thinking in the field about possible mechanisms of RTK dimerization. In particular the concept of multivalent ligands has been developed^{2,13}. More recent biophysical studies have now demonstrated this paradigm holds true for a number of RTK's^{14,15,16}. In this research I aim to complement these biophysical studies with the structural details for the case of the erbB family of RTK's. The erbB family of RTK's comprises 4 members, EGFR (erbB1), erbB2 (neu, HER-2) erbB3 and erbB4. The erbB ligands fall into two distinct classes: the EGF agonist that all bind to and activate EGFR [refs. 17-21], and the neuregulins (NRG) that bind to erbB3 and erbB4 [refs. 22-24]. To date erbB2 remains an orphan receptor. Each of the erbB ligands contains an EGF-like domain of 50-90 amino acids that, although in some cases only a small portion of the native ligand, is sufficient for its biological function. The interaction between EGF and EGFR is the best characterized of all erbB receptor/ligand complexes. Binding of monomeric EGF to the soluble extracellular domain of EGFR (s-EGFR) induces its dimerization to form a final $(\text{EGF})_2:(\text{s-EGFR})_2$ complex¹⁵. The dimerization step could occur by either of two mechanisms, which are not mutually exclusive. Dimerization could be receptor mediated, with an EGF-induced conformational change exposing a receptor-receptor interaction site. Alternatively, dimerization could be ligand-mediated, with each EGF molecule binding simultaneously to both receptors in the dimer. The reality may lie between the two extremes. The paradigm of bivalent ligands established in other studies makes the ligand-mediated model attractive. One of the most direct means of answering the question of whether EGF is mono- or bivalent in its interaction with EGFR is to solve the three dimensional structure of the entire complex.

The specific aims of this research are as follows:

- Determine the X-ray crystal structure of the EGF induced s-EGFR homodimer
- Characterize the determinants of ligand specificity of domains 1 and 3 for each of the erbB receptors using biophysical and structural approaches.
- Determine the structure of an activated heterodimer between erbB2 and another erbB family member.

Body of Annual Report

The major accomplishment of this funding period was to obtain well diffracting crystals of s-EGFR/EGF complex (see Task 4 below). In light of this, the emphasis of the research has shifted toward the determination of this structure and, at present, away from considerations of the ligand binding specificity of domains 1 and 3 of each erbB receptor (Task 3). This still interesting question will be revisited at a later time in the funding period. Progress on each task is described.

Task 1 Obtain purified receptor extracellular domains (months 1 - 18)

Recombinant baculoviruses have been generated which allow the secretion from insect cells of the full length extracellular domains of EGFR, 2, 3 and 4 (s-erbBs). C-terminal cleavable His-tags are incorporated to facilitate the first purification step using Ni-affinity chromatography. Production and purification of these proteins is routine with yields ranging from 0.3 mg/L (s-erbB2) to 1.5 mg/L (s-EGFR). Typically 5 - 10 liters of a suspension culture of Sf9 insect cells are grown, in Sf900-II medium (Gibco/BRL), to a density of 2.5×10^6 cells/ml, and infected at a multiplicity of infection (MOI) of about 5 with freshly amplified, high titer virus solution. Cultures are incubated for a further 96 hours. The clarified conditioned medium is diafiltered against 3.5 volumes of 25 mM Tris, 150 mM NaCl, pH 8.0 (buffer A), using a Millipore Prep/Scale-TFF 30 kDa cartridge and concentrated to approximately 300 ml prior to loading onto a 5 ml Ni-NTA Superflow column (Qiagen). After extensive washing with buffer A, the column is washed sequentially with 2 column volumes of buffer A containing 30, 50, 75, 100 and 300mM imidazole, pH 8.0. Typically the majority of the protein elutes in the 75 and 100 mM fractions. Fractions are concentrated in a Centrprep 30 (Amicon) and loaded on a Pharmacia Superose 6 gel filtration column. At this stage the s-erbBs are greater than 95% pure as assessed by SDS-PAGE analysis (Figure 1).




Figure 1

SDS-PAGE of the purified s-erbB proteins.

For crystallization, s-EGFR is further purified by cation exchange chromatography. Fractions from the gel filtration column are pooled, diluted 1.5 fold with 50 mM MES pH 6.0 and loaded on to a BioRad S2 sulfopropyl cation exchange column, pre-equilibrated with 25 mM MES pH 6.0. A gradient in NaCl is developed and the protein elutes at about 200 mM NaCl. The purification utilizes no harsh treatments such as those used to elute protein from antibody affinity columns, which we feel is important in generating material suitable for crystallization. Purified s-erbBs are buffer exchanged into 25 mM Hepes, 100 mM NaCl, pH 8.0, concentrated to between 20 and 100 μ M, and stored at 4° C.

Concentrations are determined by absorbance at 280 nM using the calculated extinction coefficients from number of Trp and Tyr in each protein.

Recombinant baculoviruses have also been generated to express the isolated ligand binding domain 3 from each of the four receptors. C-terminal His tags are incorporated to aid in purification of this 30 kDa domain. Domain 3 from EGFR (s-EGFRdom3) has been purified, using a procedure similar to that described above for purification of the full length receptor except that a 10 kDa molecular weight cut off cartridge, and Pharmacia Superose 12 column are employed, as is required for this much smaller (30 kDa) protein. The yield of s-EGFRdom3, about 0.2 mg/L, is lower than for full length s-EGFR. The expressed protein is also less homogeneous. The expressed protein migrates as a doublet on SDS-PAGE, as visualized by Coomassie blue staining and Western blot with antibody to the C-terminal His-tag. These two species can be separated by cation exchange chromatography (Figure 2A) but the yield at this step is low. Attempts were made to improve the homogeneity of s-EGFRdom3 by enzymatic deglycosylation using endoglycosidase H. The protein could be digested to a single species (Figure 2B), which was essentially deglycosylated, some residual sugar remained as assessed using an immunoblot kit for detecting glycoproteins from BioRad. This deglycosylated s-EGFRdom3 was however unstable and precipitated during purification attempts. At this stage further work on producing large quantities of the subdomains 1 and 3 of s-erbB receptors has been postponed while effort is diverted to other more promising areas of research (Task 5).




Figure 2 A. SDS-PAGE s-EGFRdom3. Fractions through the second of two peaks from a cation exchange purification step are shown
B. SDS-PAGE analysis showing the enzymatic deglycosylation of s-EGFRdom3 with endoglycosidase H (EndoH)

Task 2. Obtain purified ligands (months 1 - 18)

Currently we purchase all ligands from commercial sources and use them without further purification. High quality s-EGFR/EGF crystals can be grown using EGF purchased from Intergen, which is relatively inexpensive. We have available *E. coli* or yeast systems for several ligands which we will use if necessary. Work will proceed on this task as required.

Task 3. Characterize binding of ligands to isolated domains 1 and 3 (months 6 - 12)

In light of the difficulties discussed above in producing large quantities of the isolated domains there has been little progress in this task. Some preliminary fluorescence experiments have confirmed that the insect cell expressed s-EGFRdom3 has similar binding affinity for TGF α as does the domain3 generated by proteolysis from mammalian expressed s-EGFR. A preliminary crystallization screen of s-EGFRdom3/TGF α complex yielded no promising results.

Task 4. Obtain diffraction quality crystals of s-EGFR/EGF complex (months 7 -18)

Purified s-EGFR was buffer exchanged into 5mM Hepes, 25 mM NaCl, pH 8.0, and concentrated to 30 mg/ml, using a Centricon (Amicon). A 1.2 fold excess of EGF was added to give final receptor concentration of 250 μ M. Standard approaches were used to survey for conditions under which s-EGFR and s-EGFR/EGF complex might crystallize. These included the use of both sparse matrix and grid screening. Small needle like crystals were observed for the s-EGFR/EGF (1.2 fold molar excess of EGF) complex in several PEG/low pH conditions in an early screen. Under the same conditions no crystals formed for the protein alone. The presence of the EGF in the crystal has been confirmed by SDS-PAGE analysis of washed crystals. The EGF can clearly be seen and comparison with prepared standard samples indicates that the ligand to receptor stoichiometry in the crystal is approximately 1:1. Subsequent optimization of the crystallization conditions produced much larger crystals, suitable to test the diffraction quality. The best crystals grow from 10 - 15 % PEG 8000 at pH 6.0 to dimensions of about 0.5 x 0.2 x 0.08 mm. To test diffraction, crystals were transferred to a solution containing the same components as the reservoir plus 15% glycerol as cryoprotectant and frozen directly in liquid nitrogen in a nylon loop. Preliminary diffraction analysis was performed on MAR image plate detector using double mirror-monochromated/focused Cu K α X-rays from a Siemens generator. The crystals diffract to better than 3.8 Å, were of space group C2, with a = 118 Å, b = 103 Å, c = 100 Å, β = 119° and one half dimer per asymmetric unit.

Crystals have been taken to synchrotron X-ray sources (see below). From test exposures taken at the National Synchrotron Light Source (NSLS) beamline X25 it is anticipated that, with an optimal crystal, it may be possible to get data to 2.5 Å. This project now represents a key component in several beam time applications at both the National Synchrotron Light Source at Brookhaven National Laboratories and the Cornell High Energy Synchrotron Source (CHESS). It is anticipated that access to synchrotron X-rays should not be a limiting factor.

Task 5. Solve the X-ray crystal structure (months 18 - 30)

(i) Collect high resolution native data (months 18 - 24)

A complete native data set to 2.8 Å has been collected on a frozen crystal at the NSLS beam line X25 operating at 1.0 Å with a Brandeis 4-module CCD-Based detector (B4). Data were processed using DENZO and SCALEPACK²⁵. A summary of the data collection statistics is given in Table 1.

Resolution Shells		Unique Reflections	Completeness	R_{sym}	I/σ
50.00	5.60	3122	91.9	0.086	14.3
5.60	4.44	3249	97.5	0.058	19.3
4.44	3.88	3320	98.6	0.071	17.8
3.88	3.53	3287	99.2	0.092	14.3
3.53	3.27	3294	99.3	0.138	10.4
3.27	3.08	3313	99.6	0.277	6.4
3.08	2.93	3271	99.7	0.443	3.7
2.93	2.80	3250	97.0	0.481	2.3
All reflections		26106	97.8	0.087	14.3

Table 1 Data collection statistics for Native data collected at NSLS X25.

Since these data were collected larger, better crystals have been obtained which diffract to 3.5 Å on a home source. Better high resolution native data will be collected at a future synchrotron visit.

(ii) Search for heavy atom derivative (months 18 - 30)

The phase information required to calculate an electron density map, from which the structure is deduced, will be obtained by the method of multiple isomorphous replacement (MIR). In this method the positions of heavy atoms in derivatives of the crystal are used to solve the phase problem. The conventional method for obtaining heavy atom derivative is to soak the crystal in solutions containing a variety of different heavy metal ions. These ions can interact with accessible functional groups in the protein crystal such as those on methionines and histidines. For large proteins a common problem with this strategy is that too many heavy atoms bind weakly to the protein. An alternative strategy that can be used in such cases is to prereact the growth factor ligand with a heavy atom that will form a stable complex with the protein.

The first stage in initiating a heavy atom derivative search is to ensure that a crystal soaked in stabilizer without any heavy atom added is isomorphous with previously collected native data. Partial data sets were collected on our home source for a number of different stabilized crystals. Crystals which were stabilized for > 6 hours were found to be nonisomorphous with those transferred from drop to cryoprotectant and frozen immediately ($R_{\text{merge}} > 20\%$). A new native data set to 3.5 Å has been collected on our home source for use in heavy atom derivative screening. This data set is of better quality than that collected at X25. The mosaicity and the R_{sym} are both lower. A stronger data set will be collected at

the next synchrotron trip. The merging R factors (to 4.0 Å) for this data set against the various partial data sets collected varies from about 12% to 16%, indicating that there is some remaining nonisomorphism, perhaps arising from crystal to crystal variability. Great care will have to be taken to ensure that relatively small differences from the incorporated heavy atom can be detected and measured sufficiently accurately to permit interpretation of the heavy atom positions.

With this problem in mind a first round of heavy atom derivative screening has been initiated which focuses on large heavy atom complexes such as di-iodobis(ethylenediamine)diplatinum(II) nitrate (PIP), with the hope that the differences for such a derivative will be large enough to identify with confidence. Screening of potential derivatives of such compounds is on going.

An alternative strategy that would avoid the non-isomorphism problem is to generate seleno methionine containing s-EGFR. This has been done for other insect cell expressed protein²⁶. The structure could then be solved using the multiwavelegh anomalous dispersion (MAD) method, where the phasing information is obtained by measuring the anomalous differences at different wave lengths on a single crystal. Although crystal to crystal variability is not an issue, the anomalous differences are small and the diffraction intensities must be measured accurately. In light of improved quality of the data from a stabilized crystal this is a promising approach which will be explored.

A limiting factor in the progress of this portion of the research has been access to our home source, which is shared among 5 groups. Given the low symmetry and relatively weak diffraction of the s-EGFR/EGF crystals collecting a complete data set can take up to 7 days of detector time. This limitation will soon be alleviated as a new MAR detector and Seimens generator are in the final stages of installation at UPenn. In addition, a freezing system will be added to the other existing area detector opening this for use with projects that require the use of frozen crystals.

(iii) Collect heavy atom derivative data (months 18 - 30)

I have collected a data set on a crystal soaked in 0.5 mM PIP. This had as R_{merge} of 18%. Thus far no convincing heavy atom site has been identified. Further analysis is in progress.

(iv) Compute an experimental electron density map (month 30)

No experimental phases have thus far been generated. There may however soon be the possibility to attempt to use a molecular replacement method to solve the structure. Last summer the crystal structure of the first three domains of the type-1 insulin-like growth-factor receptor (IGF-1R) was reported²⁷. This receptor is highly homologous to s-EGFR. Although this structure is of the protein alone, indeed this truncated IGF-1R is not able to bind ligand, the structural homology may be sufficiently high to allow the determination of a molecular replacement solution. The coordinates for the IGF-1R structure have been on a one year hold but should become available in September.

Task 6. Build the atomic model and refine the structure (months 30 - 36)

Task 6 cannot be initiated until the phase information discussed above is obtained.

Key Research Accomplishments

- Milligram quantities of pure s-EGFR, 2, 3 and 4 can be generated
- The EGF/s-EGFR receptor dimer has been crystallized
- Native data on the EGF/s-EGFR crystals to 2.8 Å resolution has been collected.
- Several potential derivatives have been characterized.

Reportable Outcomes

Application for synchrotron X-ray beam time at National Synchrotron Light Source at Brookhaven National Laboratories - 6 days awarded

Application to use Cornell High Energy Synchrotron Source (CHESS) - proposal approved; beam time can be requested as needed.

Conclusions

Major steps have been made toward solving the crystal structure of the EGF induced s-EGFR homodimer. Knowledge of this structure will be extremely valuable in understanding not only the mechanism of activation of erbB receptors but also in designing strategies for therapeutic intervention in breast cancer.

References

1. Ullrich, A. & Schlessinger, J. (1990) Signal transduction by receptors with tyrosine kinase activity. *Cell* **61**, 203-212.
2. Heldin, C. (1995) Dimerization of cell surface receptors in signal transduction. *Cell* **80**, 213-223.
3. Lemmon, M.A. & Schlessinger, J. (1994) Regulation of signals transduction and signal diversity by receptor oligomerization. *Trends Bioc. Sci.* **19**, 459-463.
4. Pawson, T. (1995) Protein modules and signaling networks. *Nature* **373**, 573-580.
5. Kuriyan, J. & Cowburn D. (1993) The structures of SH2 and SH3 domains. *Curr. Opin. Struct. Biol.* **3**, 828-837.
6. Hubbard, S.R., Wei, L., Ellis, L. & Hendrickson, W.A. (1994) Crystal structure of the tyrosine kinase domain of the human insulin. *Nature* **372**, 746-54.
7. Mohammadi, M.; Schlessinger, J. & Hubbard, S.R. (1996) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. *Cell* **86**, 577-587.
8. Ihle, J.N. (1995) Cytokine receptor signaling. *Nature* **377**, 591-594.
9. Cunningham, B.C., Ultsch, M., de Vos, A.M., Mulkerrin, M.G., Clauser, K.R. & Wells, J.A. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. *Science* **254**, 821-825.
10. de Vos, A.M., Ultsch, M. & Kossiakoff, A.A. (1992) Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. *Science* **255**, 306-312.
11. Philo, J.S., Aoki, K.H., Arakawa, T., Narhi, L.O. & Wen, J. (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. *Biochemistry* **35**, 1681-1691.
12. Walter, M.R., Windsor, W.T., Nagabhushan, T.L., Lundell, D.J., Lunn, C.A., Zauodny, P.J. & Narula, S.K. (1995) Crystal structure of a complex between interferon- γ and its soluble high-affinity receptor. *Nature* **376**, 230-235.
13. Lemmon, M.A. & Schlessinger, J. (1997) Transmembrane signaling by receptor oligomerization. In *Methods in Molecular Biology*, Vol 84: *Transmembrane Signaling Protocols* (Bar-Sagi, D., ed.) Humana Press Inc., Totowana, NJ, pp 31-53.
14. Spivak-Kroizman, T., Lemmon, M.A., Dikic, I., Ladbury, J.E., Pinchasi, D., Huang, J., Crumley, G., Schlessinger, J. & Lax, I. (1994). Heparin-induced oligomerization of FGF molecules is responsible for FGF-receptor dimerization, activation, and cell proliferation. *Cell* **79**, 1015-1024.
15. Lemmon, M.A., Bu, Z., Ladbury, J.E., Zhou, M., Pinchasi, D., Lax, I., Engelman, D.M. & Schlessinger, J. (1997). Two EGF molecules contribute additively to stabilization of the EGFR dimer. *EMBO J.* **16**, 281-294..
16. Lemmon, M.A., Pinchasi, D., Zhou, M., Lax, I., & Schlessinger, J. (1997). Kit dimerization is driven by bivalent binding of stem cell factor. *J. Biol. Chem.* **272**, 6311-6317.
17. Lax, I., Johnson, A., Howk, R., Sap, J., Bellot, F., Winkler, M., Ullrich, A., Vennstrom, B., Schlessinger, J. & Givol, D. (1988) Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha. *Mol. Cell. Biol.* **8**, 1970-1978.
18. Plowman, G.D., Green, J.M., McDonald, V.L., Neubauer, M.G., Disteché, C.M., Todaro, G.J. & Shoyab, M. (1990) The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. *Mol. Cell. Biol.* **10**, 1969-1981.
19. Shing, Y., Christofori, G., Hanahan, D., Ono, Y., Sasada, R., Igarashi, K. & Folkman, J. (1993) Betacellulin: a mitogen from pancreatic beta cell tumors. *Science* **259**, 1604-1607.
20. Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama T. & Hanada, K. (1995) Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. *J. Biol. Chem.* **270**, 7495-7500.
21. Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C. & Klagsbrun, M. (1991) A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. *Science* **251**, 936-939.

22. Peles, E. & Yarden, Y. (1993) Neu and its ligands: From an oncogene to neural factors. *BioEssays* **15**, 815-824.
23. Chang, H., Riese, D.J., Gilbert, W., Stern, D.F. & McMahan, U.J. (1997) Ligands for erbB-family receptors encoded by a neuregulin-like gene. *Nature* **387**, 509-512.
24. Carraway, K.L., Weber, J.L., Unger, M.J., Ledesma, J., Yu, N., Gassmann, M. & Lai, C. (1997) Neuregulin-2, a new ligand of erbB3/erbB4-receptor tyrosine kinases. *Nature* **387**, 512-516.
25. Otwinowski, Z. & Minor, W. (1997) Processing of x-ray diffraction data collection in oscillation mode. *Methods Enzymol.* **276** 307-326
26. Chen, W.Y. & Bahl, O.P. (1991) Selenomethionyl analog of recombinant human choriogonadotropin. *J. Biol. Chem.* **266**, 9355-9358
27. Garrett, T.P., McKern, N.M., Lou, M., Frenkel, M.J., Bentley, J.D., Lovrecz, G.O., Elleman, T.C., Cosgrove, L.J., Ward, C.W. (1998) Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. *Nature* **394**, 395-9



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Aug 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB274369
ADB256383
ADB264003
ADB274462
ADB266221
ADB274470
ADB266221
ADB274464
ADB259044
ADB258808
ADB266026
ADB274658
ADB258831
ADB266077
ADB274348
ADB274273
ADB258193
ADB274516
ADB259018
ADB231912
ADB244626
ADB256677
ADB229447
ADB240218
ADB258619
ADB259398
ADB275140
ADB240473
ADB254579
ADB277040
ADB249647
ADB275184
ADB259035
ADB244774
ADB258195
ADB244675
ADB257208
ADB267108
ADB244889
ADB257384
ADB270660
ADB274493
ADB261527
ADB274286
ADB274269
ADB274592
ADB274604

ADB274596
ADB258952
ADB265976
ADB274350
ADB274346
ADB257408
ADB274474
ADB260285
ADB274568
ADB266076
ADB274441
ADB253499
ADB274406
ADB262090
ADB261103
ADB274372